In 2016, the Food and Drug Administration (FDA) made the move to digitization by requiring the collection and submission of datasets for nonclinical studies to be filed electronically in a standardized, consistent format. Known as the Clinical Data Interchange Standards Consortium (CDISC) Standard for Exchange of Nonclinical Data (SEND), this …
Welcome to the digital future of pathology
Imagine getting a phone call in the middle of your study from a scientist who is seeing something completely unexpected in your study results. You need to make a decision on how to move forward and you need to do it quickly. You don’t have time to wait for a …
Harnessing efficiencies and intelligence for your study
Let us pull back the curtain for just a moment. There are hundreds, if not thousands, of different actions and pieces of data that need to be completed, collected, processed, organized and tracked over the duration of your study or program. That information has to be accessible by dozens of …
Application of decentralized clinical trials on AI-focused dermatology
Leveraging AI-focused dermatology in decentralized clinical trials The use of virtual tools and telecommunications skyrocketed during the COVID-19 pandemic as the world adjusted to new ways of working. In the clinical trials sector, this propelled an increasing adaptation to the decentralized clinical trial (DCT) approach to support research and minimize …
The evolution of Central Laboratory planning and forecasting to enable more efficient study delivery
Fostering trust with customers starts with delivering study materials on time, underscoring the importance of planning and forecasting processes to meet current demands. While the pandemic highlighted the need to adjust approaches and address the industry’s supply chain disruptions, it also brought forth enhanced planning and forecasting methods at Labcorp. …
NHS England’s Rare Disease Action Plan: Renewed Focus on Access to Innovative Drugs
In England, February 2022 has seen the lifting of all COVID-19 restrictions. As we cautiously enter a “new normal” after the disruption caused by the pandemic, there is renewed focus on previous healthcare priorities. The development and commercialization of innovative treatments for rare diseases has long been an area of …
Cell & gene therapy answers: Preclinical oncology
Your source for answers on how to assess the preclinical efficacy of cell therapies. Watch the video > As the landscape of cell therapy continues to evolve, so are the tools to assess the efficacy of cell therapy in the preclinical space. To better understand Labcorp’s preclinical oncology role in …
Advancing inhalation toxicology capabilities to support chemical testing
Respiratory exposure to chemicals or agrochemicals poses potential risk to human health, especially to workers handling these products. Whether preparing a solution, dusting or spraying crops, or cleaning equipment, opportunities for inadvertent inhalation is a risk that can potentially lead to toxic effects, both acute and chronic. That’s why identifying …
Eight Instrument Considerations in Flow Cytometry
Whether it’s developing fit-for-purpose, customized flow assays, or optimizing the most appropriate off-the-shelf assay, the Labcorp Central Laboratory Services flow cytometry specialty testing team generates high-quality, clinically relevant and actionable data for your drug development programs. Here, we discuss how we choose our flow cytometry instruments to execute multi-site operations …
Labcorp Patient Access Solutions Asembia discussions for 2022
Marking progress since Asembia 2021 At industry events, there are the discussions you hear inside of sessions, and there are also the discussions that take place outside of sessions. During the October 2021 Asembia event, we heard several common themes among attendees, clients, prospects and vendors: Balancing digital innovation and …